Everest Medicines Limited (HKG:1952)
Hong Kong · Delayed Price · Currency is HKD 48.98
+0.52 (1.07%)
Oct 31, 2025, 4:08 PM HKT
Everest Medicines Revenue
Everest Medicines had revenue of 446.12M CNY in the half year ending June 30, 2025, with 4,915.44% growth. This brings the company's revenue in the last twelve months to 851.28M, up 103.39% year-over-year. In the year 2024, Everest Medicines had annual revenue of 706.68M with 461.16% growth.
Revenue (ttm)
851.28M CNY
Revenue Growth
+103.39%
P/S Ratio
18.55
Revenue / Employee
1.28M CNY
Employees
665
Market Cap
17.30B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 706.68M | 580.75M | 461.16% |
| Dec 31, 2023 | 125.93M | 113.14M | 884.46% |
| Dec 31, 2022 | 12.79M | 12.74M | 23,588.89% |
| Dec 31, 2021 | 54.00K | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| JD Health International | 71.34B |
| BeOne Medicines AG | 35.81B |
| Sino Biopharmaceutical | 33.49B |
| Alibaba Health Information Technology | 32.81B |
| CSPC Pharmaceutical Group | 28.49B |
| WuXi Biologics | 21.98B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| Innovent Biologics | 12.52B |
Everest Medicines News
- 7 months ago - AI-powered Cancer Vaccine In The Works - Benzinga
- 1 year ago - Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update - Benzinga